

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Claims 17-20 are canceled without prejudice or disclaimer.


Claims 1-16 are amended.

Claims 21-30 are new.

Listing of Claims:


1) (Currently Amended) Compound derived from 2-thiohydantoin, ~~characterized in that it which is selected from:~~

a) compounds of the formula



in which


- R₁ or R₂ each independently is
 - a linear, branched or cyclic C₁-C₅ alkyl group,
 - a C₃-C₄ alkenyl group,
 - a C₂-C₃ hydroxyalkyl group or one of its precursor groups,
 - a C₃-C₅ alkoxyalkyl group,
 - a CH₂-COOCH₃ group,
 - an N,N-dialkylaminoalkyl group,
 - a group



in which m is 2 or 3 and Y is O or N-CH₃,

- a dibenzofuranyl group, or
- a group (CH₂)_p-Ar, in which
 - p is 0 or 1, and

Ar is a phenyl or pyridinyl aromatic ring that is unsubstituted or substituted by one or more atoms or groups of atoms selected from halogens, C₁-C₄ alkyl, hydroxyl, nitro, C₁-C₃ alkoxy, methylenedioxy, SCH₃, free or esterified carboxylic acid, trifluoromethyl, trifluoromethoxy, cyano, morpholinyl and



in which

A is O, S, CH₂, OCH₂ or CH₂O,

X is CH or N, and

R₅ is a hydrogen atom, a halogen atom, an N,N-dialkylamino group, a C₁-C₄ alkyl group, a C₁-C₃ alkoxy group, a hydroxyl group that is free or esterified by an amino acid, or a carboxyl or alkoxy(C₁-C₄)carbonyl group;


- R₃ is a hydrogen atom, a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a hydroxyl group, a phenyl group or a benzyl group; and
- R₄ is a hydrogen atom, a halogen atom or a C₁-C₄ alkyl group,

with the proviso that at least one of the substituents R₁ and R₂ comprises in its structure 2 aromatic rings selected from phenyl and pyridinyl groups, the dibenzofuranyl group being considered here as comprising 2 aromatic rings; and

- b) addition salts of the compounds of formula (I) with a non-toxic acid if said compounds of formula (I) comprise a salifiable basic group.


2. (Currently Amended) Compound derived from 2-thiohydantoin, characterized in that it which is selected from:

- a) compounds of the formula




in which

- R₁ and R₂ independently of one another are
 - a C₁-C₅ alkyl group,
 - a C₃-C₄ alkenyl group,
 - a C₂-C₃ hydroxyalkyl group,
 - a C₃-C₅ alkoxyalkyl group,
 - a CH₂-COOCH₃ group,
 - an N,N-dialkylaminoalkyl group,
 - a group



in which m is 2 or 3 and Y is O or N-CH₃,

- a dibenzofuranyl group, or
- a group (CH₂)_p-Ar in which
 - p is 0 or 1, and
 - Ar is a phenyl or pyridinyl aromatic ring that is unsubstituted or substituted by one or more atoms or groups of atoms selected from halogens, C₁-C₄ alkyl, hydroxyl, nitro, C₁-C₃ alkoxy, methylenedioxy, ester, trifluoromethyl, trifluoromethoxy, cyano, morpholinyl and the group



in which


- A is O or S,
- X is CH or N, and
- R₅ is a hydrogen atom, a halogen atom, an N,N-dialkylamino group, a C₁-C₃ alkoxy group or a hydroxyl group that is free or esterified by an amino acid;
- R₃ is a hydrogen atom, a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a hydroxyl group, a phenyl group or a benzyl group; and
- R₄ is a hydrogen atom, a halogen atom or a C₁-C₄ alkyl group,

with the proviso that at least one of the substituents R₁ and R₂ comprises in its structure 2 aromatic rings selected from phenyl and pyridinyl groups, or is the dibenzofuranyl group; and

b) addition salts of the compounds of formula (I) with a non-toxic acid if said compounds of formula (I) comprise a salifiable basic group.

3. (Currently Amended) Compound according to claim 2, characterized in that it which is selected from:

a) compounds of the formula




in which

R₁ is

- a C₃-C₄ alkenyl group,
- a dibenzofuranyl group, or
- a group (CH₂)_n-Ar in which

n is 0 or 1, and

Ar is a phenyl or pyridinyl aromatic ring that is unsubstituted or substituted by one or more atoms or groups of atoms selected from halogens, C₁-C₄ alkyl, nitro, C₁-C₃ alkoxy, C₃-C₄ alkoxyalkyl and the group



in which

A is O or S,


X is C or N, and

R₅ is a hydrogen atom, a halogen atom, an N,N-di(C₁-C₃)alkylamino group, a C₁-C₃ alkoxy group or a hydroxyl group that is free or esterified by an amino acid;

R₂ is

- a C₁-C₅ alkyl group,

- a C₃-C₄ alkenyl group,
- a C₂-C₃ hydroxyalkyl group,
- a C₃-C₅ alkoxyalkyl group,
- a CH₂-COOCH₃ group,
- a group N,N-di(C₁-C₃)alkylamino(C₁-C₃)alkyl,
- a group




in which m is 2 or 3 and Y is O or N-CH₃, or

- a group (CH₂)_p-Ar in which

p is 0 or 1, and

Ar is a phenyl or pyridinyl aromatic ring that is unsubstituted or substituted by one or more atoms or groups of atoms selected from halogens, C₁-C₄ alkyl, hydroxyl, nitro, C₁-C₃ alkoxy, methylenedioxy, ester, trifluoromethyl, trifluoromethoxy, cyano, morpholinyl and the group




in which

B is O or S;

- R₃ is a hydrogen atom, a halogen atom, a C₁-C₄ alkyl group, a C₁-C₄ alkoxy group, a hydroxyl group, a phenyl group or a benzyl group; and
- R₄ is a hydrogen atom, a halogen atom or a C₁-C₄ alkyl group,
with the proviso that at least one of the substituents R₁ and R₂ comprises in its structure 2 aromatic rings selected from phenyl and pyridinyl groups, or R₁ is the dibenzofuranyl group; and
 - b) addition salts of the compounds of formula (I) with a non-toxic acid if said compounds of formula (I) comprise a salifiable basic group.

4. (Currently Amended) Compound derived from 2-thiohydantoin, characterized in that it which is selected from the compounds of formula (I):




in which

R₁ and R₂ independently of one another are

- a C₁-C₅ alkyl group,
- a C₃-C₄ alkenyl group, or
- a group -(CH₂)_n-Ar in which

n is 0 or 1, and

Ar is a phenyl ring that is unsubstituted or substituted by one or more atoms or groups of atoms selected from halogens, C₁-C₄ alkyl, nitro, C₁-C₃ alkoxy, methylenedioxy, carboxyl or alkoxy(C₁-C₄)carbonyl, and



in which


A is CH₂O or OCH₂, and

R₅ is a hydrogen atom, a halogen atom, a C₁-C₄ alkyl group, a C₁-C₃ alkoxy group or a carboxyl or alkoxy(C₁-C₄)carbonyl group; and

R₃ and R₄ each independently are a hydrogen atom or a C₁-C₄ alkyl group,

with the proviso that at least one of the substituents R₁ and R₂ comprises 2 aromatic rings in its structure.


5. (Currently Amended) Compound according to claim 4, characterized in that it which is selected from the compounds of formula (I):



in which

- R₁ is
 - a C₃-C₄ alkenyl group, or
 - a group -(CH₂)_n-Ar in which
- n is 0 or 1, and

Ar is a phenyl ring that is unsubstituted or substituted by one or more atoms or groups of atoms selected from halogens, C₁-C₄ alkyl, nitro, C₁-C₃ alkoxy, carboxyl or alkoxy(C₁-C₄)carbonyl, and



in which


A is CH₂O or OCH₂, and

R₅ is a hydrogen atom, a halogen atom, a C₁-C₄ alkyl group, a C₁-C₃ alkoxy group or a carboxyl or alkoxy(C₁-C₄)carbonyl group;

- R₂ is

- a C₁-C₅ alkyl group,
- a C₃-C₄ alkenyl group, or
- a group -Ar in which

Ar is a phenyl ring that is unsubstituted or substituted by one or more atoms or groups of atoms selected from halogens, C₁-C₄ alkyl, nitro, C₁-C₃ alkoxy, methylenedioxy, carboxyl or alkoxy(C₁-C₄)carbonyl, and




in which

B is CH₂O or OCH₂; and

- R₃ and R₄ each independently are a hydrogen atom or a C₁-C₄ alkyl group, with the proviso that at least one of the substituents R₁ and R₂ comprises 2 aromatic rings in its structure.

6. (Currently Amended) Compound derived from 2-thiohydantoin, characterized in that it which is selected from:

- a) the compounds of formula (I):




in which

- R₁ and R₂ independently of one another are
 - a C₁-C₅ alkyl group,
 - a C₃-C₄ alkenyl group,
 - a C₂-C₃ hydroxyalkyl group or one of its precursors,
 - a C₃-C₅ alkoxyalkyl group, or
 - a group (CH₂)_p-Ar in which

p is 0 or 1, and

Ar is a phenyl or pyridinyl aromatic ring that is unsubstituted or substituted by one or more atoms or groups of atoms selected from halogens, hydroxyl, nitro, cyano, C₁-C₃ alkoxy, carboxyl, alkoxy(C₁-C₄)carbonyl, methylthio, methylenedioxy and



in which

X is CH or N, and

R₅ is a hydrogen atom, a halogen atom, a C₁-C₃ alkoxy group or a hydroxyl group; and


- R₃ and R₄ each independently are a hydrogen atom or a C₁-C₄ alkyl group,

with the proviso that at least one of the substituents R₁ and R₂ comprises in its structure 2 aromatic rings selected from phenyl and pyridinyl groups; and

b) addition salts of the compounds of formula (I) with a non-toxic acid if said compounds of formula (I) comprise a salifiable basic group.

7. (Currently Amended) Compound according to claim 6, characterized in that it which is selected from:

a) the compounds of formula (I):




in which

R₁ is

- a C₃-C₄ alkenyl group, or
- a group (CH₂)_n-Ar in which

n is 0 or 1, and

Ar is a phenyl aromatic ring that is unsubstituted or substituted by one or more atoms or groups of atoms selected from halogens, C₁-C₃ alkoxy, nitro and the group



in which

X is CH or N, and


R₅ is a hydrogen atom, a halogen atom, a C₁-C₃ alkoxy group or a hydroxyl group;

R₂ is

- a C₁-C₅ alkyl group,
- a C₃-C₄ alkenyl group,
- a C₂-C₃ hydroxyalkyl group or one of its precursors,
- a C₃-C₅ alkoxyalkyl group, or
- a group (CH₂)_p-Ar in which

p is 0 or 1, and

Ar is a phenyl or pyridinyl aromatic ring that is unsubstituted or substituted by one or more atoms or groups of atoms selected from halogens, hydroxyl, nitro, cyano, C₁-C₃ alkoxy, carboxyl, alkoxy(C₁-C₄)carbonyl, methylthio, methylenedioxy and



and

R₃ and R₄ each independently are a hydrogen atom or a C₁-C₄ alkyl group, with the proviso that at least one of the substituents R₁ and R₂ comprises in its structure 2 aromatic rings selected from phenyl and pyridinyl groups; and

b) addition salts of the compounds of formula (I) with a non-toxic acid if said compounds of formula (I) comprise a salifiable basic group.

8. (Currently Amended) Compound according to claim 1, characterized in that in which one of the radicals R₁ or R₂ is the phenoxyphenyl, phenylthiophenyl, (phenylmethoxy)phenyl or (phenylmethyl)phenyl group and the radicals R₃ and R₄ and the other radical R₁ or R₂ are as defined in claim 1 [or 2].

9. (Currently Amended) Compound according to claim 2 or 3, characterized in that in which one of the radicals R₁ or R₂ is the phenoxyphenyl or phenylthiophenyl group and the radicals R₃ and R₄ and the other radical R₁ or R₂ are as defined in claim 2 [or 3].


10. (Currently Amended) Compound according to claim 4 or 5, characterized in that in which one of the radicals R₁ or R₂ is the phenoxyphenyl, phenylthiophenyl, (phenylmethoxy)phenyl or (phenylmethyl)phenyl group and the radicals R₃ and R₄ and the other radical R₁ or R₂ are as defined in claim 4 [or 5].

11. (Currently Amended) Compound according to claim 6 or 7, characterized in that in which one of the radicals R₁ or R₂ is the phenoxyphenyl, phenylthiophenyl, (phenylmethoxy)phenyl or (phenylmethyl)phenyl group and the radicals R₃ and R₄ and the other radical R₁ or R₂ are as defined in claim 6 or 7.


12. (Currently Amended) Compound of formula (I) according to ~~any one of claims 1 to 4, characterized in that claim 1, in which~~ R₃ is a methyl group and R₄ is a hydrogen atom or a methyl group.

13.(Currently Amended) Process for the preparation of a compound of formula (I) according to ~~any one of claim[s] 1 to 12, characterized in that claim 1, wherein~~ it comprises steps which consist in:


- a) reacting an acid of the formula



in which R₁ and R₄ are as defined above in claim 1 and R₃ is H, C₁-C₄ alkyl, phenyl or benzyl, with an isothiocyanate of formula (III):



in which R₂ is a group as defined above in claim 1, in a solvent, at a temperature between 20°C and the boiling point of the solvent, in the presence of a base, for 1 to 20 hours, to give the compound of formula (I):




in which R₁, R₂, R₃ and R₄ are as defined for the starting materials; and


- b) if necessary, if the compound of formula (I) obtained above contains a salifiable basic group such as an amine, reacting said compound with a mineral or organic acid, in an anhydrous solvent, to give the salt of the compound of formula (I).

14.(Currently Amended) Process for the preparation of a compound of formula (I) according to any one of claims 1 to 12, characterized in that claim 1, wherein it consists in:


a) reacting an ester of formula (IV):



in which R₁ and R₄ are as defined in claim 1, R₃ is H, C₁-C₄ alkyl, phenyl or benzyl and R is a C₁-C₄ alkyl group, preferably a methyl, ethyl or isopropyl group, with an isothiocyanate of formula (III):



the reaction being carried out in a solvent, in the presence of a weak acid, at a temperature between 80°C and the boiling point of the solvent, for 0.5 to 5 hours, to give the compound of formula (I):



in which

R₁, R₂, R₃ and R₄ are as defined for the starting compounds; and

b) if necessary, in the case where the compound of formula (I) comprises a salifiable basic group, reacting said compound with an acid to give the corresponding salt.

15. (Currently Amended) Pharmaceutical composition, characterized in that which it contains at least one compound of formula (I) according to any one of claims 1 to 12 claim 1 in association with at least one physiologically acceptable excipient.

16. (Currently Amended) Compound of formula (I) or one of its addition salts with a pharmaceutically acceptable acid, according to any one of claims 1 to 12 claim 1, as a pharmacologically active substance.

17. (Cancelled)

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (New) Method for the treatment of diabetes and diseases due to hyperglycemia, which consists in administering to a patient in need thereof an effective amount of a compound of formula (I) according to claim 1, or one of its addition salts with a pharmaceutically acceptable acid.

22. (New) Method for the treatment of hypertriglyceridemia and dyslipidemia which consists in administering to a patient in need thereof an effective amount of a compound of formula (I) according to claim 1, or one of its addition salts with a pharmaceutically acceptable acid.

23. (New) Method for the treatment of obesity which consists in administering to a patient in need thereof an effective amount of a compound of formula (I) according to claim 1, or one of its addition salts with a pharmaceutically acceptable acid.

24. (New) Method for the treatment of cerebral vascular accidents which consists in administering to a patient in need thereof an effective amount of a compound of formula (I) according to claim 1, or one of its addition salts with a pharmaceutically acceptable acid.

25. (New) Compound according to claim 3, in which one of the radicals R₁ or R₂ is the phenoxyphenyl or phenylthiophenyl group and the radicals R₃ and R₄ and the other radical R₁ or R₂ are as defined in claim 3.

26. (New) Compound according to claim 5, in which one of the radicals R₁ or R₂ is the phenoxyphenyl, phenylthiophenyl, (phenylmethoxy)phenyl or (phenylmethyl)phenyl group and the radicals R₃ and R₄ and the other radical R₁ or R₂ are as defined in claim 5.

27. (New) Compound according to claim 7, in which one of the radicals R₁ or R₂ is the phenoxyphenyl, phenylthiophenyl, (phenylmethoxy)phenyl or (phenylmethyl)phenyl group and the radicals R₃ and R₄ and the other radical R₁ or R₂ are as defined in claim 7.

28. (New) Compound of formula (I) according to claim 2 in which R₃ is a methyl group and R₄ is a hydrogen atom or a methyl group.

29. (New) Compound of formula (I) according to claim 3 in which R₃ is a methyl group and R₄ is a hydrogen atom or a methyl group.

30. (New) Compound of formula (I) according to claim 4 in which R₃ is a methyl group and R₄ is a hydrogen atom or a methyl group.